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ALIGNING YOUR HEALTH SYSTEM'S CONFLICT
OF INTEREST POLICIES WITH THE PHYSICIAN
PAYMENT SUNSHINE ACT
James G. Scott' and Andrejs E. Avots-Avotins"
I. INDUSTRY-PROVIDER RELATIONSHIPS-A MIXED MESSAGE
Advancements in clinical research and patient outcomes are possible
when manufacturers of drugs, medical devices, and biologics collaborate
with health providers. Relationships between the manufacturers of drugs,
devices, biologicals, and medical supplies;' and individual physicians and
medical centers produce numerous opportunities for the exchange of
valuable clinical information and feedback necessary for the advancement of
clinical decision-making and patient care.2 Patients benefit from the first-
hand knowledge these practitioners and their respective institutions bring to
the practice of medicine.3  These collaborations, however, often involve
financial arrangements, which include financial or professional incentives.
These incentives can also pose possible conflicts of interest that can lead to a
treatment bias or a clinical decision that favors the use of one device or drug
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1. See Social Security Act § 1128G(a)(1)(A)(vii), 42 U.S.C. § 1320a-
7h(a)(1)(A)(vii) (2006).
2. See generally CONFLICT OF INTEREST IN MEDICAL RESEARCH, EDUCATION, AND
PRACTICE (Inst. of Med. ed., 2009).
3. Id.
39
40 The Journal of Contemporary Health Law and Policy Vol. XXVIII: 1
over another.4 In these situations, the practitioners' motives may be in
question, and their decisions and viewpoints are potentially compromised.5
Conflicts of interest arising from physicians' relationships with industry
vary but generally are financial in nature or involve professional gain in the
form of increased visibility, peer recognition, or preferential treatment.6
Financial conflicts of interest occur when physicians are tempted to deviate
or do deviate from their professional obligations for economic or other
personal gain.7 "Although most physicians deny that receiving free lunches,
subsidized trips, or other gifts from industry has any effect on their practices,
research has shown [it] does influence prescribing behavior."8
Conflicts can also vary by the physician's practice setting. One survey
showed that physicians in solo, two-person, or group practices were
significantly more likely to have relationships with industry than were
physicians in hospitals or clinics.9 Possible results of conflicts include
prescribing brand-name drugs instead of cheaper and equivalent generic
drugs; using drug samples for off-label use; adopting novel treatments
before sufficient evidence is available; ignoring evidence-based guidelines;
and promoting a "culture of entitlement" based on financial ties with
industry.10  The press has exposed industry and investigators' failure to
disclose negative research data or financial relationships." Universities,' 2
4. Id.
5. Troyen Brennan et al., Health Industry Practices That Create Conflicts of
Interest, 295 JAMA 429, 433 (2006).
6. Id.
7. Id. at 430.
8. Eric Campbell, Doctors and Drug Companies-Scrutinizing Influential
Relationships, 357 NEw ENG. J. MED. 1796, 1797 (2007).
9. Eric Campbell et al., A National Survey ofPhysician-Industry Relationships, 356
NEw ENG. J. MED. 1742, 1746 (2007).
10. Campbell, supra note 8, at 1796.
11. See Brennan, supra note 5.
12. See AAMC-AAU ADVISORY COMM. ON FINANCIAL CONFLICTS OF INTEREST IN
HUMAN SUBJECTS RESEARCH, PROTECTING PATIENTS, PRESERVING INTEGRITY,
ADVANCING HEALTH: ACCELERATING THE IMPLEMENTATION OF COI POLICIES IN HUMAN
Conflict ofInterest Policies and the PPSA
sponsors,' and medical journalsl4 have policies which require disclosure of
all financial relationships in order to assess potential conflicts of interest.
For the most part, these relationships and their impact on clinical
decision-making are not well known or understood by the public.'5
Furthermore, disclosure of potential conflicts does not completely resolve
the problem.' Most patients do not have sufficient scientific knowledge to
discern if a possible conflict exists despite disclosure of the relationship.17
Allowing these conflicts to continue erodes the integrity of the medical
profession and undermines society's confidence in health providers and their
decisions.
The Physician Payment Sunshine Act,'8 included in the Patient Protection
and Affordable Care Act,19 is intended to eliminate potential conflicts of
interest and minimize the bias in treatment choices believed to increase
health care costs. Scott & White Healthcare, the largest multidisciplinary
health system in Texas, has implemented a conflict of interest policy to
assist its employees in identifying conduct that might give rise to a conflict.
SUBJECTS RESEARCH 1 (2008) [hereinafter AAMC-AAU COI POLICIES],
http://www.aau.edu/WorkArea/DownloadAsset.aspx?id=6136.
13. See Responsibility of Applicants for Promoting Objectivity in Research for
which Public Health Service Funding is Sought and Responsible Prospective Contractors,
76 Fed. Reg. 53,256 (Aug. 25, 2011) (codified at 42 C.F.R. pt. 50 and 42 C.F.R. pt. 94).
14. See Jeffrey M. Drazen et al., Uniform Format for Disclosure of Competing
Interests in ICMIE Journals, 361 NEw ENG. J. MED. 1896, 1896 (2009), available at
http://www.nejm.org/doi/full/10.1056/NEJMe0909052.
15. See Brennan, supra note 5.
16. Id. at 431.
17. Id.
18. Social Security Act § I 128G, 42 U.S.C. § 1320a-7h (2006).
19. Patient Protection and Affordable Care Act, Pub. L. No. 111-148, 124 Stat. 119
(2010), as amended by the Health Care Education Reconciliation Act, Pub. L. No. 111-
152, 98 Stat. 1585 (2010) (codified at 42 U.S.C.A. § 18001 (West 2011)).
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II. MAGNITUDE OF THE PROBLEM
Campbell and colleagues reported that in a 2004 study of 3167 physicians,
94 percent of them were involved in some type of relationship with the
pharmaceutical industry.2 0  Physicians reported receiving food and
beverages in the workplace (83 percent); being given drug samples by a
manufacturer's representative (78 percent); receiving reimbursement for
costs associated with professional meetings or continuing education (35
percent); and receiving payments for consulting, speaking, or enrolling
patients in trials (28 percent).21 Although a follow-up study by the same
authors reported a decline in relationships to 84 percent, financial
arrangements between industry and physicians remain common and
unreported.22
Similarly, physician-industry relationships are prevalent in industry-
sponsored research. According to the National Institutes of Health, nearly
52 percent of all researchers had relationships with industry in 2007,
amounting to nearly double the 28 percent who had such relationships in
1996.23
III. EFFORTS TO ADDRESS CONFLICTS OF INTEREST
Eliminating conflicts of interest is of growing interest to policy makers
24and professional societies. From a policy perspective, the debate centers
on the effect of these relationships on patient care and health care costs.25 A
growing number of biomedical ethicists, medical students, journalists, and
elected officials have demanded increased transparency through public
reporting of financial relationships at institutional, state, and national
20. Campbell, supra note 9, at 1742.
21. Id. at 1746.
22. Eric Campbell, Physician Professionalism and Changes in Physician-Industry
Relationships from 2004-2009, 170 ARCHIVES INTERNAL MED. 1820, 1826 (2010).
23. Scott Harris, New Conflict of Interest Rules Help Spur Financial Disclosures
Online, Ass'N OF AM. MED. COLLS. (Mar. 21, 2011), https://www.aamc.org/
newsroom/reporter/june10/136280/new conflict of interestruleshelpspur financial
disclosures.html.
24. Campbell, supra note 8.
25. Id.
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levels. 26 Recently, professional societies, state and federal legislators, and
academic-based organizations issued guidelines or regulations to address
conflicts of interest and minimize the likelihood of their influence in clinical
practice and research.27
A. Institute of Medicine
In 2007, the Institute of Medicine ("IOM") appointed the Committee on
Conflict of Interest in Medical Research, Education, and Practice to examine
conflicts of interest in medicine and to recommend steps to identify, limit,
and manage conflicts of interest without negatively affecting constructive
collaborations.28 The IOM report emphasizes that a preventative rather than
a reactive approach to conflicts of interest is preferred.29 The Committee
recommends: a) disclosure of industry-to-medical-institution financial ties,
including academic medical centers, professional societies, patient advocacy
groups and medical journals; b) standardization of disclosure content,
format, and procedure; and c) enactment of federal legislation that creates a
national reporting program requiring pharmaceutical, medical device, and
biotechnology companies to make public all payments to physicians,
researchers, health care institutions, professional societies, patient advocacy
and disease groups, and providers of continuing education.
In addition, the IOM recommends that researchers should not conduct
research involving human participants if they have a financial interest in the
outcome.3 1 Because academic medical centers have a major responsibility
for training future physicians and medical staff, their objectivity and
scientific integrity is of the utmost importance.3 2 To reduce the risk of bias,
the IOM recommends that teaching hospitals prohibit faculty from accepting
26. Eric Campbell, Public Disclosure of Conflicts of Interest: Moving the Policy
Debate Forward, 170 ARCHIVES INTERNAL MED. 667, 675 (2010).
27. See Campbell, supra note 8.
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gifts, making presentations, and entering into consulting arrangements not
governed by written contracts for specific consulting services to be paid at
fair market value.33 The IOM recommends that health insurers, accrediting
bodies, and government agencies develop incentives for policy changes that
promote transparency in the development of clinical guidelines and
accountability in the nature and disclosure of relationships with industry.34
B. Professional Authorities
In 2008, the American Association of Medical Colleges ("AAMC") and
the Association of American Universities ("AAU") released the report
Protecting Patients, Preserving Integrity, Advancing Health: Accelerating
the Implementation of COI Policies in Human Subjects Research. The
report calls on all medical schools and major research universities to develop
and implement financial conflicts of interest policies and to refine standards
for addressing individual financial conflicts.
In May 2010, the National Institutes of Health ("NIH") issued a notice of
proposed rulemaking to edit current regulations to "strengthen accountability
and transparency of current financial conflict of interest rules at the
government, institutional and investigator level."36 On a conference call to
answer stakeholder questions regarding the proposed rule, NIH Director
Francis Collins said that "partnerships between NIH-funded researchers and
industry are essential;" the regulations seek to manage these partnerships to
reduce financial conflict of interest and intervene when necessary. 37 The
proposed changes would increase transparency in financial interest
disclosure and enhance compliance and oversight. On August 25, 2011,
NIH finalized these proposed changes to the regulations.39
33. Id.
34. See generally CONFLICT OF INTEREST IN MEDICAL RESEARCH, EDUCATION, AND
PRACTICE, supra note 2.
35. See AAMC-AAU COI POLICIES, supra note 12.
36. Financial Conflict of Interest, U.S. DEP'T OF HEALTH & HUMAN SERVS.,
http://grants.nih.gov/grants/policy/coil (last updated Dec. 2, 2010).
37. Press Briefing, Financial Conflict of Interest Notice of Proposed Rulemaking
(May 20, 2010), available at http://grants.nih.gov/grants/policy/coilbriefing transcript-
%2805202010%29.htm.
38. Responsibility of Applicants for Promoting Objectivity in Research for which
Public Health Service Funding Is Sought and Responsible Prospective Contractors, 75
Conflict ofInterest Policies and the PPSA
C. State Laws Enacted
In 1993, Minnesota became the first state to mandate industry disclosure
of payments related to medical conferences, honoraria, compensation
connected to research, or any payment totaling $100 or more to physicians.40
Other states, including Vermont, Maine, Massachusetts, West Virginia, and
the District of Columbia, have implemented guidelines for disclosing
physician-industry relationships.41 A recent review of Vermont's law
showed gifting was limited to a few major corporations and that less than
two percent of the state's prescribers received 69 percent of the gifts and
payments. Companies were notably generous to specialists in psychiatry,
endocrinology e.g., diabetes and metabolic disorders), internal medicine,
and neurology.4  Despite the enactment of a federal disclosure law in 2010
that preempts those portions of state laws that are duplicative or weaker, but
does not preempt more restrictive provisions, 43 state lawmakers continue to
introduce legislation requiring industry to disclose gifts and compensation to
physicians with whom they have consultation and education relationships."
Fed. Reg. 28,688 (proposed May 21, 2010) (to be codified at 42 C.F.R. pt. 50 and 45
C.F.R. pt. 94).
39. Responsibility of Applicants for Promoting Objectivity in Research for which
Public Health Service Funding Is Sought and Responsible Prospective Contractors, 76
Fed. Reg. 53,256 (finalized Aug. 25, 2011) (codified at 42 C.F.R. pt. 50 and 45 C.F.R. pt.
94).
40. Susan Chimonas et al., Show us the Money: Lessons in Transparency from State
Pharmaceutical Marketing Disclosure Laws, 45 HEALTH SERV. RESEARCH 98, 98-114
(2010).
41. Id. at 98.
42. Id.
43. See Social Security Act § 1128G(d)(3), 42 U.S.C. § 1320a-7h(d)(3) (2006).
44. Payment Sunshine: Ohio State Senator Introduces "Payment Disclosure"
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This patch-work of state laws has led to a call for a national system of
disclosure.45
D. Federal Legislation Enacted
To provide for a consistent and understandable national system of
46disclosure, the Physician Payment Sunshine Act ("PPSA") was enacted in
the Patient Protection and Affordable Care Act of 2010 ("PPACA").4 7
48Championed by Senator Chuck Grassley and Senator Herb Kohl, the law
requires pharmaceutical and medical device manufacturers (i.e., "industry")
to disclose financial relationships with physicians and teaching hospitals. In
introducing the bill that was later to become part of the PPACA, Senator
Grassley paraphrased Justice Brandeis by stating "Sunlight is the best
disinfectant."
The PPSA requires that, beginning no later than March 13, 2013, and on
the 90 day of each subsequent year, U.S. manufacturers of covered drugs,
devices, biologicals, or medical supplies report electronically to the
Secretary of the Department of Health and Human Services ("HHS"), who
has delegated this function to the Centers for Medicare & Medicaid Services
("CMS"), the following payments or transfers of value to physicians or
teaching hospitals:50 consulting fees;5 1 compensation for services other than
45. See 155 CONG. REC. S788 (daily ed. Jan. 22, 2009) (statement of Sen. Charles
Grassley on introduction of S. 301).
46. Id.
47. Patient Protection and Affordable Care Act, Pub. L. No. 111-148, § 6002, 124
Stat. 119 (2010), as amended by the Health Care Education Reconciliation Act, Pub. L.
No. 111-152, 98 Stat. 1585 (2010) (codified at 42 U.S.C.A. §1320a-7h (West 2011))
(adding section I 128G of the Social Security Act).
48. Physician Payment Sunshine Act Introduced, POL'Y & MED. (Jan. 22, 2009),
http://www.policymed.com/2009/01/physician-payment-sunshine-act-2009-
introduced.html.
49. See 155 CONG. REc. S788 (daily ed. Jan. 22, 2009) (statement of Sen. Charles
Grassley on introduction of S. 301); see also Louis D. BRANDEIS, OTHER PEOPLE'S
MONEY: AND How THE BANKERS USE IT 92 (1914) ("Sunlight is said to be the best of
disinfectants . . . .").
50. See Social Security Act § 1128G(a)(1)(A), 42 U.S.C. § 1320a-7h(a)(1)(A)
(2006).
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consulting;52  honoraria;5 3  gifts;5 4  entertainment;5 5  food;S6 travel;5
education; research; charitable contributions;60 royalties or licenses; 6 1
current or prospective ownership or investment interests;62 direct
compensation for serving as faculty or as a speaker for a medical education
51. See Social Security Act § 1128G(a)(1)(A)(vi)(I), 42 U.S.C. § 1320a-
7h(a)(1)(A)(vi)(I).
52. See Social Security
7h(a)(1)(A)(vi)(II).
53. See Social Security
7h(a)(1)(A)(vi)(III).
54. See Social Security
7h(a)(1)(A)(vi)(IV).
55. See Social Security
7h(a)(1)(A)(vi)(V).
56. See Social Security
7h(a)(1)(A)(vi)(VI).
57. See Social Security
7h(a)(1)(A)(vi)(VII).
58. See Social Security
7h(a)(1)(A)(vi)(VIII).
59. See Social Security
7h(a)(1)(A)(vi)(IX).
60. See Social Security
7h(a)(1)(A)(vi)(X).
61. See Social Security
7h(a)(1)(A)(vi)(XI).
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program;63 grants; and any other nature of the payment or transfer of value
as defined by the Secretary.65
The PPSA requires manufacturers to begin collecting data on payments
66and transfers of value starting on January 1, 2012. The law also required
the Secretary of HHS to establish procedures by October 1, 2011, for
manufacturers to disclose information to the Secretary and for the Secretary
to make that information available to the public.67 Included in the
disclosure, among other things, is the name of the physician or hospital and
the value of the payment. 68 Thus far, neither HHS nor CMS has established
those procedures. In its response to a congressional inquiry as to the reason
for the missed statutory deadline, CMS Administrator Berwick stated that
CMS is working to implement the statutory provision, but did not provide
further details on when a proposed rule or any other guidance would be
issued.69 As of the writing of this article, the Office of Management and
Budget is reviewing CMS' proposed rule.70
The PPSA does not require disclosure if industry provides valuable
consideration indirectly to a physician or teaching hospital through a third
party in conjunction with an activity or service if the manufacturer is
unaware of the identity of the recipient or if the product is for patient use and
not intended to be sold.71
63. See Social Security Act § 1128G(a)(1)(A)(vi)(XIII), 42 U.S.C. § 1320a-
7h(a)(1)(A)(vi)(XIII).
64. See Social Security Act § 1128G(a)(1)(A)(vi)(XIV), 42 U.S.C. § 1320a-
7h(a)(1)(A)(vi)(XIV).
65. See Social Security Act § 1128G(a)(1)(A)(vi)(XV), 42 U.S.C. § 1320a-
7h(a)(1)(A)(vi)(XV).
66. See Social Security Act § 1128G(a)(1)(A), 42 U.S.C. § 1320a-7h(a)(1)(A).
67. See Social Security Act § 1128G(c)(1)(A), 42 U.S.C. § 1320a-7h(c)(1)(A).
68. See Social Security Act § 1128G(a)(1)(A)(i), 42 U.S.C. § 1320a-7h(a)(1)(A)(i).
69. See Letter from Donald Berwick to Sen. Herb Kohl (Oct. 28, 2011),
http://policymed.typepad.com/files/sunshineactcmsresponse.pdf.
70. See List of Regulatory Actions Currently Under Review, REGINFO.GOV.,
http://www.reginfo.gov/public/jsp/EO/eoDashboard.jsp (last visited Dec. 12, 2011).
71. See Social Security Act § 1128G(e)(10)(A), 42 U.S.C. § 1320a-7h(e)(10)(A).
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Payments are excluded if they are less than $10, or in aggregate, amount
7'to less than $100 in the prior year. 72 The law directs CMS to construct an
online database and begin posting the collected data beginning September
13, 2013, and on June 30 of each subsequent year.n The data collected is to
be searchable in a clear, understandable, and downloadable manner. 74
Further, it is to include any penalties imposed or actions taken to ensure
compliance.7 5 Information relatinf to relationships formed for clinical
research is to be reported separately.
Penalties for noncompliance are monetary and vary depending on the
severity and intent of noncompliance. Failing to report correctly the
required information in a timely manner may result in fines of up to $10,000,
not to exceed $150,000 annually. Knowingly failing to report the required
information may result in fines of up to $100,000, not to exceed $1 million
annually.79
The Act also requires applicable manufacturers and group purchasing
organizations (distributors are excluded) to disclose information regarding
ownership and investment interests held by a physician (or immediate family
member) in the manufacturer or group purchasing organization during the
preceding year.80
72. See Social Security Act § 1128G(e)(10)(B)(i), 42 U.S.C. § 1320a-
7h(e)(1 0)(B)(i).
73. See Social Security Act § I 128G(c)(1)(C), 42 U.S.C. § 1320a-7h(c)(1)(C).
74. See id.
75. See Social Security Act § 1128G(c)(1)(C)(iv), 42 U.S.C. § 1320a-
7h(c)(1)(C)(iv).
76. See Social Security Act § 1128G(c)(1)(C)(vi), 42 U.S.C. § 1320a-
7h(c)(1)(C)(vi).
77. See Social Security Act § I 128G(b), 42 U.S.C. § 1320a-7h(b).
78. See Social Security Act § I 128G(b)(1), 42 U.S.C. § 1320a-7h(b)(1).
79. See Social Security Act § I128G(b)(2), 42 U.S.C. § 1320a-7h(b)(2).
80. See Social Security Act § I 128G(a)(2), 42 U.S.C. § 1320a-7h(a)(2).
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E. Academic Medical Centers Respond
Academic medical centers are uniquely positioned to take a leadership
role in eliminating conflicts of interest due to their organizational structure
and responsibility for medical training.8 They also are highly involved in
clinical research and are hubs for patient referrals in a wide range of
specialties. 82 In response to professional recommendations and in light of
state and federal legislation, teaching hospitals are voluntarily implementing
conflict of interest policies that address the concerns of policy makers and
professional societies.83
IV. Scorr & WHITE HEALTHCARE'S PERSPECTIVE
Scott & White Healthcare, serving patients in a nearly 30,000 square mile
area of central Texas, is the largest multispecialty health care system in the
state.84 It owns eight hospitals, affiliates with four more, and recently broke
ground for a new hospital in College Station, Texas, all of which
cumulatively admit 50,000 total inpatients annually.85 Scott & White also
operates 60 regional primary and specialty care clinics, receiving 2.1 million
annual outpatient visits, and a 240,000-member health plan. Scott & White
Memorial Hospital also serves as the teaching hospital for the Texas A & M
Health Science Center College of Medicine and has a growing division of
research conducting in excess of 400 active clinical studies, the majority of
which are funded by industry.86 Founded in Temple, Texas, in 1897, the
physician-led nonprofit system employs more than 11,000 staff, including
nearly 900 physicians and scientists.
87
81. See Brennan, supra note 5.
82. Id.
83. See, e.g., Scorr & WHITE HEALTHCARE, CONFLICT OF INTEREST POLICY (2011)
[hereinafter CONFLICT OF INTEREST POLICY], http://researchers.sw.org/resources/docs/
research/COI-Policy-02-01-2011 .pdf.
84. About Us, Scorr & WHITE HEALTHCARE, http://www.sw.org/about-us/about-us
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In August 2008, The Commonwealth Fund Commission on a High
Performance Health System released a report that examined problems
engendered by fragmentation in the health care system and offered policy
recommendations to stimulate greater organization for high performance.
Scott & White was one of 15 case-study sites that the Commission examined
to illustrate the six attributes identified as the ideal health care delivery
system in a diverse organizational setting.89
Scott & White recently took steps to update its conflict of interest policy
to address better the disclosure of conflicts and the institution's expectations
of relationships with industry. After careful consideration, a revised conflict
of interest policy90 was approved in February 2011. The revised conflict of
interest policy attempts to eliminate conflicts of interest in several ways,
including: 1) designating a specific department to receive and distribute
industry donations of monies or items of value that are intended for
educational or developmental use or patient care (e.g., training funds,
charitable gifts, medical equipment); 2) requiring prior approval at the
department chair level for certain activities such as speaking engagements or
industry sponsored travel; 3) prohibiting blatant and direct financial
offerings that are not commensurate with an exchange of professional
services (e.g., payment for attendance only at an industry-sponsored
meeting); and 4) requiring prior approval of agreements with third parties. 91
Key provisions of the new conflict of interest policy that may be
applicable to other teaching hospitals and physician groups include
provisions detailing disclosures, prohibited items, allowable items, and other
features of the policy.
A. Disclosures
Scott & White employees are required to complete a Conflict of Interest
Disclosure Form and keep it up-to-date with current information.92
Guidelines for relationships and interactions with industry are specific and
88. See generally ANTHONY SHIH ET AL., THE COMMONWEALTH FUND COMM'N ON A
HIGH PERFORMANCE HEALTH SYS., ORGANIZING THE U.S. HEALTH CARE DELIVERY
SYSTEM FOR HIGH PERFORMANCE (2008).
89. Id. at 15.
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apply to all employees, not just physicians.93 Relationships involving Scott
& White intellectual property are closely scrutinized and any rifhts, titles, or
interests cannot be assigned or transferred without permission.9
B. Prohibited Items
Personal gifts from industry are prohibited, including entertainment,
recreation, and non-approved travel.95 Additionally, Scott & White's policy
prohibits industry funding for meals on-site, and guidelines are provided for
participation in off-site, industry-sponsored programs or meetings where a
meal is included.96 Honoraria for continuing education provided to Scott &
White personnel, or provided in a non-Scott & White venue where Scott &
White pays travel and expenses, are not permitted . However, if Scott &
White does not pay for travel and expenses, then the speaker has the
opportunity to accept the honorarium, subject to the department chair's
approval.
C. Allowable Items
Donations of equipment and money are allowed but must be coordinated
through a central office.99 Decisions regarding distribution are made by
those with no involvement in the donor industry.100 Drug samples are also
permissible but may only be delivered to non-patient care areas in facilities
where the samples will be disbursed.10 Pharmaceutical representatives may










102. CONFLICT OF INTEREST POLICY, supra note 83.
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receipt and distribution of all drug samples, devices, or monetary donations
must be carefully documented. 0 3
Industry has long been involved in funding educational and research
activities for medical staffs. 104 This practice remains permissible at Scott &
White if the activity is intended to facilitate training of employees, students,
and residents.'05  Funds are collected by the Development Office and
distributed by the department chair.106 The receipt of such donations (but
not the amount) may be made public.'07
Scott & White employees may participate in industry-sponsored speakers'
bureaus, but the department chair must pre-approve that participation.10 8
Accepting Xayment solely to attend an industry-sponsored event is
prohibited.' Industry funding for travel expenses also requires
preauthorization by the traveler's department chair and is limited to product
evaluations, site assessments, etc.o10 Employees must consult with the Legal
Department prior to entering into verbal or written agreements to serve as a
speaker or to provide technical skills, consulting, clinical expertise, or
related assistance for industry.'1 '
D. Other Features of the Conflict ofInterest Policy
Integral to the conflict of interest policy is a detailed explanation on how
to determine whether a conflict of interest exists.l12 Experience has shown
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another." 3 Much care is taken in the conflict of interest policy to parse
through the internal processes available to all employees who question their
involvement with industry, whether it is seemingly innocent or not.114 As
noted in the IOM report, providing guidance that eliminates a conflict of
interest before it happens is preferred over correcting the problem later on."s
The integrity of Scott & White's research program and its standing in the
academic community is of paramount importance. The conflict of interest
policy affirms that the safety and welfare of human subjects involved in
clinical trials and the integrity of research at Scott & White should not be
subordinated to, or compromised by, financial or other personal interests.116
Many of the guidelines for employees conducting research mirror those
recommended by the AAMC and AAU. 17 Investigators are encouraged to
disclose any situation that could conceivably be viewed as a conflict of
interest as early as possible."' 8  Scott & White prefers that investigators
disclose a potential conflict rather than try and "second guess" whether a
conflict exists.'' 9 Research at Scott & White involves a wide range of
funding sources, from governmental agencies to private entities and other
universities, making it impossible for any one investigator to know fully of
the potential conflicts or risks for the institution at large.120
Specifically, investigators must disclose financial interests (including
salary, consulting fees, honorarium, stocks, equity interests, ownerships,
intellectual property rights, royalties, etc.) for themselves and for their
spouses or domestic partners and dependent children. 121 If the financial
113. Id.
114. CONFLICT OF INTEREST POLICY, supra note 83.
115. See CONFLICT OF INTEREST IN MEDICAL RESEARCH, EDUCATION, AND PRACTICE,
supra note 2.
116. See CONFLICT OF INTEREST POLICY, supra note 83.
117. See AAMC-AAU COI POLICIES, supra note 12.
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interests of other family members are known, they must be disclosed as
well.122 Disclosure is also required of sub-grantees, contractors, or
collaborators who conduct research on Scott & White's behalf.123
The goal was to design a policy that eliminates the potential bias of
working with industry but encourages the advancement in medical
knowledge.12 4 Thus, 8ractical applications for compliance and reporting
were also considered. s The conflict of interest policy is to be included in
the employee's annual review.' 26
V. PREPARING FOR THE PHYSICIAN PAYMENT SUNSHINE ACT
With the enactment of the Physician Payment Sunshine Act, financial
relationships between industry, teaching hospitals, and physicians will be
required to be disclosed to the federal government and made public in
2013.127 While the duty to report rests with industry,128 teaching hospitals
should revise their conflict of interest policies with the goal of addressing
the concerns that the federal law intends to correct.
First, teaching hospitals have a heightened interest in eliminating conflicts
of interest due to their extensive research interests and responsibilities for
training and educating future practitioners. They should establish or revise
conflict of interest protocols using professional guidelines such as the
AAMC-AAU recommendations.129 Although industry has the duty to
disclose financial relationships under the new federal law, teaching hospitals
share an equal, if not greater, responsibility for upholding patient welfare,
maintaining research integrity, and lowering health care costs by virtue of
the high frequency of direct patient contact in such hospitals and their
responsibility for training future physicians and medical staff.
122. Id.
123. Id.
124. CONFLICT OF INTEREST POLICY, supra note 83.
125. Id.
126. Id.
127. See Social Security Act § 1128G(c)(1)(C), 42 U.S.C. § 1320a-7h(c)(1)(C)
(2006).
128. See Social Security Act § 1 128G(c)(1)(A)(i), 42 U.S.C. § 1320a-7h (c)(1)(A)(i).
129. See AAMC-AAU COI POLICIES, supra note 12.
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Second, teaching hospitals should identify a physician who is responsible
for explaining and securing support for the conflict of interest policy across
the institution. Scott & White has found that physicians are receptive to
their peers and can offer each other guidance and feedback on the policy's
implementation and adoption. Conflict of interest policies should not be
viewed as a deterrent, but rather an important step in maintaining an
institution's commitment to high-quality, unbiased patient care.
Third, institutions should share their conflict of interest policy with
industry partners and work collaboratively to ensure that the policies are
understood and enforced. Collaborative relationships and frequent, open-
door discussions may also ensure that industry's disclosure to CMS under
PPSA will be accurate and fair. Establishing these relationships early on
will help expedite the "review and correct"l 30 process CMS will provide to
industry and teaching hospitals prior to the public release of registry data.
Lastly, institutions should educate their consumers, referring physicians,
and patients about their relationships with industry and help them understand
both the importance of these relationships and the steps being taken to avoid
concerns. One approach Scott & White plans to utilize is disclosing
physician-industry relationships on the "Find-a-Provider" portion of its
website.1 31  Institutions should also be prepared to offer assistance
interpreting CMS data once it is publicly available in a manner that conveys
a sense of trust, accountability, and a commitment to patient welfare.
VI. CONCLUSION
Eliminating conflicts of interest in physician-industry relationships is of
growing importance. With the enactment of the Physician Payment
Sunshine Act, teaching hospitals should develop conflict of interest policies
that strengthen the collaborative exchange of knowledge with industry,
while eliminating the opportunity for bias in clinical decision-making and
research. Scott & White Healthcare's efforts as an operator of a major
teaching hospital in Temple, Texas, are one way hospitals and physician
groups may move in this direction.
130. See Social Security Act § 1 l28G(c)(1)(D), 42 U.S.C. § 1320a-7h(c)(1)(D).
131. Provider Directory, Scorr & WHITE HEALTHCARE, http://www.sw.org/provider-
search (last visited Dec. 12, 2011).
